BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25885405)

  • 1. Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis.
    Rupoli S; Goteri G; Picardi P; Micucci G; Canafoglia L; Scortechini AR; Federici I; Giantomassi F; Da Lio L; Zizzi A; Honorati E; Leoni P
    Diagn Pathol; 2015 Apr; 10():29. PubMed ID: 25885405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
    Kamiunten A; Shide K; Kameda T; Ito M; Sekine M; Kubuki Y; Hidaka T; Akizuki K; Tahira Y; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Shimoda H; Yamashita K; Matsuoka H; Shimoda K
    Int J Hematol; 2018 Oct; 108(4):411-415. PubMed ID: 29987745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
    Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
    J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.
    Finazzi G; Carobbio A; Thiele J; Passamonti F; Rumi E; Ruggeri M; Rodeghiero F; Randi ML; Bertozzi I; Vannucchi AM; Antonioli E; Gisslinger H; Buxhofer-Ausch V; Gangat N; Rambaldi A; Tefferi A; Barbui T
    Leukemia; 2012 Apr; 26(4):716-9. PubMed ID: 21926959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.
    Barbui T; Thiele J; Carobbio A; Passamonti F; Rumi E; Randi ML; Bertozzi I; Vannucchi AM; Gisslinger H; Gisslinger B; Finazzi G; Ruggeri M; Rodeghiero F; Rambaldi A; Gangat N; Tefferi A
    Blood; 2012 Jul; 120(3):569-71. PubMed ID: 22700720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis.
    Guglielmelli P; Carobbio A; Rumi E; De Stefano V; Mannelli L; Mannelli F; Rotunno G; Coltro G; Betti S; Cavalloni C; Finazzi MC; Thiele J; Cazzola M; Vannucchi AM; Barbui T
    Blood Cancer J; 2020 Feb; 10(2):21. PubMed ID: 32098944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan.
    Edahiro Y; Araki M; Inano T; Ito M; Morishita S; Misawa K; Fukuda Y; Imai M; Ohsaka A; Komatsu N
    Eur J Haematol; 2019 Jun; 102(6):516-520. PubMed ID: 30977935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study.
    Zhang L; Ye X; Luo S; Xu X; Wang S; Jin K; Zheng Y; Zhu X; Chen D; Jin J; Huang J
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2383-2392. PubMed ID: 35731275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
    Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.
    Kc D; Falchi L; Verstovsek S
    Ann Hematol; 2017 Oct; 96(10):1595-1604. PubMed ID: 28808761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Leukemia; 2013 Oct; 27(10):1953-8. PubMed ID: 23467025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.
    Jeryczynski G; Thiele J; Gisslinger B; Wölfler A; Schalling M; Gleiß A; Burgstaller S; Buxhofer-Ausch V; Sliwa T; Schlögl E; Geissler K; Krauth MT; Nader A; Vesely M; Simonitsch-Klupp I; Müllauer L; Beham-Schmid C; Gisslinger H
    Am J Hematol; 2017 Sep; 92(9):885-891. PubMed ID: 28543356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.
    Barosi G; Rosti V; Bonetti E; Campanelli R; Carolei A; Catarsi P; Isgrò AM; Lupo L; Massa M; Poletto V; Viarengo G; Villani L; Magrini U
    PLoS One; 2012; 7(4):e35631. PubMed ID: 22536419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volumetric splenomegaly in patients with essential thrombocythemia and prefibrotic/early primary myelofibrosis.
    Lee MW; Yeon SH; Ryu H; Song IC; Lee HJ; Yun HJ; Kim SY; Lee JE; Shin KS; Jo DY
    Int J Hematol; 2021 Jul; 114(1):35-43. PubMed ID: 33704663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Utility of the bone marrow biopsy in the diagnosis of essential thrombocytemia].
    Rager O; Parrens M; Brière J; Lippert E; Milpied N; Pellegrin JL; Viallard JF
    Presse Med; 2011 Dec; 40(12 Pt 1):e507-15. PubMed ID: 21737230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WHO classification of myeloproliferative neoplasms (MPN): A critical update.
    Kvasnicka HM
    Curr Hematol Malig Rep; 2013 Dec; 8(4):333-41. PubMed ID: 24146204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis.
    Brousseau M; Parot-Schinkel E; Moles MP; Boyer F; Hunault M; Rousselet MC
    Histopathology; 2010 May; 56(6):758-67. PubMed ID: 20546341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
    Michiels JJ
    Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.